Destiny Pharma PLC Posting of Annual Report and Notice of AGM (4389X)
April 29 2019 - 8:28AM
UK Regulatory
TIDMDEST
RNS Number : 4389X
Destiny Pharma PLC
29 April 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Posting of Annual Report and Accounts, and Notice of AGM
Brighton, United Kingdom - 29 April 2019 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), announces that the
annual report and accounts of the Company for the year ended 31
December 2018 ("Annual Report"), and the notice of the Company's
Annual General Meeting ("AGM") are now available on the Company's
website at www.destinypharma.com
The Annual Report will be posted to shareholders today.
The AGM is to be held at 10.00am on 4 June 2019 at the offices
of finnCap Limited, 60 New Broad Street, London EC2M 1JJ.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About XF-73
XF-73 is a synthetic anti-microbial active against all tested
Staphylococcus aureus strains, including drug resistant strains. By
acting via a cell-surface mechanism it affects the bacterial
membrane permeability and integrity, leading to cell death. XF-73
has already been through five successful Phase I/IIb clinical
trials showing rapid antibacterial action. In standard microbiology
studies XF drugs have demonstrated a unique no/low resistance
profile that means that XF compounds have the potential to deliver
novel drugs that are clearly differentiated from traditional
antibiotics where resistance limits their utility.
XF-73 is being studies for the prevention of post-surgical
staphylococcal infections. In the US, there are approximately 40
million surgeries per annum alone where the patient is at risk of a
post-surgical infection. However, within this large population
there are particular groups who are at an even higher risk of
infection due to the nature of their surgery or the procedures
and/or their specific hospital environment in which they are
treated. These higher risk surgical procedures include
cardiovascular, orthopaedic and other complex surgeries. Destiny
Pharma estimates that this totals approximately 14 million US
surgeries per year, with this figure set to rise within the context
of an ageing population.
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCILMJTMBTTBFL
(END) Dow Jones Newswires
April 29, 2019 09:28 ET (13:28 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024